2026-11-09 · 2026-11 / week-2

Berkshire’s Q3 underwriting drop is real; the short still lacks a downside bound

Berkshire’s Q3 underwriting drop is real; the short still lacks a downside bound

Classification: Reject / no-trade screen. Berkshire Hathaway’s Q3 insurance-underwriting earnings fell 42.9% year over year, and its Class B shares closed at 1.596 times September book value. But nine-month operating earnings grew 8.0%, cash and Treasury bills were $352.3 billion, and Berkshire repurchased about $9.65 billion of stock in Q3 by my reconstruction of its filing table. A mechanical return to the 20-year median price-to-book ratio offers 11.6% downside, while the recent five-year upper range implies 12.2% upside. The base case is flat; the short fails 10/5 before borrowing and execution costs.

Run time: Nov. 9, 2026, 00:58 Singapore time

Market observation: BRK.B regular-session close of $570.89 on Nov. 6, 2026, 4:00 p.m. Eastern (21:00 UTC), before the Nov. 7 results release.

Scope: U.S.-listed short opportunities only. No broker order is authorized.

Opportunity Ranking

Candidates are ranked by information value. None qualifies as a short.

Rank Candidate Direction Mispricing Evidence Freshness Catalyst Window Positioning 10/5 Status Tradeability Main Rejection Risk
1 Berkshire Hathaway (BRK.B) Short screen Q3 underwriting earnings fell 42.9%, while the Nov. 6 close implies 1.596x Q3 book value; the 20-year median P/B is lower, but 9M operating earnings rose 8.0%. High: Nov. 7 release and Q3 10-Q; Friday close. First regular session after the Nov. 7 release is Nov. 9; next earnings date not verified. Q3 issuer buybacks derived at ~$9.65B; current holder, short, borrow and options positioning unknown. Reject: flat base, +12.2% adverse case, 0.96:1 gross reward/adverse. NYSE common stock; post-result quote, spread, depth, locate and exit capacity unverified. A strong diversified business can hold or expand its multiple; the buyback program has no commitment but remains a potential support.
2 NRG Energy (NRG) Short screen Shares closed at $88.29 after a 9.6% Friday rebound, following two declines; Q3 results are due before Monday’s open. Q2 guidance remained intact. High: official Q2 results and event schedule; Nov. 6 close. Nov. 9, 8:00 a.m. ET results and call. Current short interest, borrow and event positioning not verified. Reject: no sourced 10% base decline with a ≤5% adverse bound. NYSE common stock; earnings gap and borrow risks unresolved. Affirmed guidance, a sharp rebound and power-market sensitivity can create a squeeze.
3 Occidental Petroleum (OXY) Short screen Shares fell 6.7% from Nov. 3 to Nov. 6 before Q3 results; Q2 debt fell to $11.8B and cash flow benefited from higher realized oil prices. High: official Q2 results and Q3 schedule; Nov. 6 close. Nov. 9 after market close; call Nov. 10. Current short, borrow, options and oil-hedge positioning not verified. Reject: no responsible 10/5 map before the event. NYSE common stock; earnings gap, commodity exposure and borrow unverified. Oil-price and production outcomes can reverse the recent decline.
4 SPDR S&P 500 ETF (SPY) Broad-market short control The Nov. 6 close was $735.29, down 2.5% from Nov. 3; no issuer-specific disagreement or catalyst is established here. High: Nov. 6 historical daily row. No specific catalyst in this screen. Broad flows and dealer exposure not reviewed. Reject: no differentiated 10/5 thesis. Broad ETF; current execution data not checked. A short would be a macro view without a sourced edge.

Selected opportunity: BRK.B is the highest-information rejected short screen, not the best executable opportunity.

Why this one now: Berkshire released a new quarter over the weekend. The filing reveals a sharp insurance setback and lets the book-value calculation be refreshed before the first post-result regular session.

What should surprise the reader: Berkshire spent about $9.65B buying stock in Q3, at a reconstructed weighted-average price of about $502.69 per B-equivalent share. That is meaningful issuer demand, but it is neither a price floor nor a commitment to keep buying near $571.

The Market Price

The Nov. 6 historical daily row shows BRK.B at $570.89, with a $559.61–$575.12 range and 5.42M shares traded. ChartExchange’s separate 3:59:54 p.m. at-close tile showed $571.12; StockAnalysis’ historical page identifies S&P Global Market Intelligence as its price-data source. I use the completed daily close, not the earlier tile or an after-hours mark. Berkshire released its Q3 results on Saturday, Nov. 7, so this quote predates the new information and is reference-only. Shares gained 5.2% from the Oct. 30 close to Nov. 6. ChartExchange historical prices · StockAnalysis historical prices and data-source note

At Sept. 30, Berkshire reported $761.368B of shareholders’ equity attributable to Berkshire and 1,418,900 equivalent Class A shares outstanding. Since each Class A share is economically equivalent to 1,500 Class B shares, the Class B book-value calculation is:

$761.368B ÷ (1,418,900 × 1,500) = $357.73 per B share.

The $570.89 reference close therefore equals 1.596x that book value. This is a Desk calculation, not a market quote or a valuation the company endorses. Price-to-book is an incomplete measure for a company whose assets include operating businesses and a large, market-valued securities portfolio; book value is not liquidation value. Berkshire Q3 Form 10-Q

The Mispricing

The bear evidence is concentrated, not broad. Q3 after-tax insurance-underwriting earnings were $1.352B versus $2.369B a year earlier, a 42.9% decline. Insurance investment income also fell 14.1% to $2.734B. The 10-Q reports GEICO’s Q3 loss ratio rose 5.1 percentage points to 76.6%, as claims frequency and average severity increased while average earned premiums per policy declined. If that pressure persists, insurance profitability could remain below the level implied by a premium valuation multiple. Berkshire Q3 earnings release · Berkshire Q3 Form 10-Q

The counterevidence matters more than the headline net-earnings comparison. After-tax operating earnings were $12.705B in Q3, down 5.8%, but $37.034B for the first nine months, up 8.0%. Q3 BNSF, Berkshire Hathaway Energy and manufacturing, service and retailing earnings all rose year over year. Net earnings fell 28.2%, but the company says investment gains and losses from market price changes have little analytical or predictive value for periodic operating performance. A short thesis built on GAAP net earnings alone would overstate the deterioration. Berkshire Q3 earnings release · Berkshire Q3 Form 10-Q

The price-to-book comparison is a sensitivity, not proof of mispricing. TGMCharts estimates a 20-year median P/B of 1.41 and a five-year range of 1.16–1.79. Its displayed current ratio uses June 30 book value, so I do not reuse that current figure. I apply the historical anchors to the newer September book value above. This treats book value as unchanged through the four-week scenario window and ignores changes in securities marks, retained earnings and share count. The historical range does not cap future prices, and the median is not intrinsic value. TGMCharts BRK.B P/B history and methodology

A competing signal is capital allocation. Berkshire’s Q3 table lists monthly Class A and B repurchases. Converting Class A shares to B-equivalent shares and multiplying each class’s disclosed count by its reported average price gives an estimated Q3 spend of $9.646B for 19.189M B-equivalent shares, or about $502.69 per share. The company separately reports $14.4B of repurchases in the first nine months. Those purchases were below the Nov. 6 close, but management can stop: Berkshire says it repurchases only when its CEO, after consulting the chair, judges price below conservatively determined intrinsic value; no minimum amount is promised. Cash, cash equivalents and Treasury bills were $352.3B at quarter-end. The buyback is evidence of past demand, not a guaranteed floor. Berkshire Q3 Form 10-Q

Positioning

The observable positioning fact is issuer repurchase activity. The share price had risen 5.2% over the last five sessions before the release, but that does not establish crowding. I did not verify current beneficial ownership, short interest, borrow availability or cost, recall terms, options exposure, dealer hedging or fund flows. I therefore make no squeeze or forced-selling claim. The missing borrow and flow evidence caps confidence and blocks execution.

Why the Price Could Move More Than 5% Soon

The first full regular session after Saturday’s results is Monday, Nov. 9. The 42.9% drop in quarterly underwriting earnings and higher GEICO loss ratio could prompt a repricing; a large, diversified company with nine-month operating growth and $352.3B of cash and Treasury bills could instead absorb the weakness. The cited historical P/B anchors show that an 11.6% decline is mechanically possible if the multiple returns to its 20-year median, but they do not establish the probability or timing of that move. The weekend release creates an observable test, not a directional edge by itself.

Catalyst Ladder

Step State and timing Observable test Failure or delay
First post-release session Scheduled for Nov. 9; no regular-session response to the Nov. 7 report existed at publication. Compare the completed session with Friday’s $570.89 reference and monitor the insurance segment, not GAAP net income alone. A flat or higher close would show that the first reaction did not validate a short; one session cannot settle valuation.
Next quarterly filing Q4 reporting cycle; exact date not verified. Track GEICO loss ratio, earned premiums, claims frequency/severity, insurance underwriting earnings and consolidated operating earnings. A return toward the prior-year 71.5% GEICO loss ratio and continued 9M-like operating growth would weaken the short thesis.
Repurchase disclosure Next quarterly filing; amount is discretionary. Verify whether purchases continue and compare the average repurchase price with the contemporaneous market price and disclosed book value. No purchase is not a sell signal; resumed purchases are not a guaranteed floor.

The cheapest falsification test is the next filed insurance bridge. One day of market reaction is useful for price discovery but cannot prove that the long-term earnings path has changed.

Price Target and Probability Map

This is a four-week reference-only sensitivity through Dec. 7, 2026, using the Nov. 6 regular close. It keeps September book value at $357.73 per B share across all scenarios. The top case uses TGMCharts’ estimated 20-year median P/B of 1.41; the bottom case uses its estimated upper end of the recent five-year range, 1.79; the base keeps the current calculated 1.596 multiple. The assumed ratios and unchanged book value are not forecasts or fair-value estimates.

The 20% / 60% / 20% probabilities are subjective judgments, not observed frequencies. The median-reversion case gets 20% because the current multiple is above that anchor but nine-month operating earnings remain positive. The flat base gets 60% because the new quarter is mixed and the release has not yet traded in regular hours. The upper-range case gets 20% because cash, operating growth and the issuer’s recent purchases can sustain or lift the multiple. This is a low-confidence map; changing the probabilities or accounting for future book growth can materially change expected value.

Scenario Probability Target / Level Return / Payoff Horizon Conditions Evidence Quality
Top Case 20% $504.39 (1.41x current book/share) +11.65% short return Four weeks, through Dec. 7, 2026 Multiple contracts to the estimated 20-year median while book/share stays constant. Low
Base Case 60% $570.89 (1.596x current book/share) 0.00% short return Four weeks, through Dec. 7, 2026 Market absorbs the mixed quarter and holds the current multiple. Low
Bottom Case 20% $640.33 (1.79x current book/share) -12.16% short return Four weeks, through Dec. 7, 2026 Cash, diversified earnings and share repurchases support a move to the estimated upper end of the recent five-year P/B range. Low
Invalidation n/a Rebuild rather than use a price stop n/a At the next filing or material new evidence GEICO’s loss ratio returns toward 71.5%, insurance underwriting stabilizes and operating earnings continue to grow; or new book/share and market data invalidate these anchors. Medium

Probability-weighted expected value: $571.48 reference terminal price, equivalent to about -0.10% gross short return before costs. The displayed probabilities sum to 100%; this is a subjective scenario average, not a calibrated expectation.

Current market level and timestamp: $570.89, Nov. 6, 2026, 4:00 p.m. ET (21:00 UTC), regular-session close.

Primary instrument: BRK.B common stock; research only.

10/5 favorable base move: 0.0% decline, below the required 10%. The top-case decline is 11.65%, but it is not the highest-probability case.

10/5 credible adverse move: +12.16% underlying rise in the bottom case, beyond the 5% bound.

Gross reward/adverse ratio: 0.96:1, below 2:1.

10/5 measurement basis: Reference-only; entry.price is null.

10/5 status: Reject / no trade.

Confidence: Low. The map depends on historical P/B estimates, subjective probabilities and a constant-book assumption; current borrow and post-result execution data are missing.

10/5 Asymmetry Gate

The highest-probability scenario is flat, not a 10% decline. The 12.16% adverse rise exceeds the policy limit, and the gross reward/adverse ratio is 0.96:1. The -0.10% weighted price-only short return is before spread, slippage, borrow, recall or carrying costs; those costs would not rescue the map. Reject the short even if Monday’s first reaction is lower.

The Kill Shot

Strongest counterargument: The market may be valuing Berkshire’s earning power and capital flexibility, not merely its book value. Nine-month operating earnings grew 8.0%; BNSF, BHE and manufacturing/service/retailing improved in Q3; cash and Treasury bills were $352.3B; and management spent about $14.4B on share repurchases in the first nine months. Q3 weakness is concentrated in insurance, with GEICO claims costs rising against lower earned premiums. It could reverse without a broad earnings decline.

Load-bearing assumption: Q3’s insurance deterioration persists long enough to reduce normalized earnings and compress the market multiple. A single quarter does not establish that. The assumption fails if GEICO prices catch up with claim severity, loss frequency normalizes, or other businesses continue to grow.

What Could Go Wrong

The price can rise even if underwriting stays weak. Berkshire’s cash, operating businesses, equity portfolio and discretionary repurchases can support investor demand. Book value itself moves with equity prices, retained earnings, repurchases and accounting marks, so the static denominator can understate either upside or downside. The P/B history is an approximate secondary series, not a company valuation policy.

A short also faces unlimited theoretical loss, a gap past any planned exit, trading halts, a recall or unavailable borrow, widening spreads and poor exit liquidity. A stop cannot bound a weekend or event gap. No locate, borrow rate, recall terms, live spread, depth, venue quality or executable post-result quote was verified. Options, leverage, margin and market orders are outside this screen.

What Would Prove This Wrong

Retire the underwriting short if the next filing shows GEICO’s loss ratio returning toward 71.5%, premiums catching up with claims, insurance underwriting earnings stabilizing and consolidated operating earnings continuing to grow. Rebuild the valuation from then-current equity, share count and market price; do not reuse this static book-value map. Strong price action alone is not proof that operations improved, but it is a reason to stop treating multiple compression as an imminent catalyst.

No-Trade Strategy

There is no pending order and no entry. Keep entry.price null and execution disabled. Re-screen only after the first post-result session and the next insurance disclosure. Any future short review must establish a current quote, spread, depth, venue and exit capacity, plus locate, borrow cost and recall terms. A new map must still show a 10% highest-probability decline, no credible adverse rise beyond 5%, at least 2:1 gross reward to adverse risk and positive expected value after costs.

Research Quality Scorecard

Criterion Score Evidence-based reason
Market disagreement 3/5 A fresh underwriting decline contrasts with a multiple above long-run P/B markers, but does not prove investor expectations are wrong.
Evidence base 5/5 Nov. 7 issuer release and 10-Q, read with the Nov. 6 market close.
Positioning and flows 2/5 Issuer buybacks are filed; current ownership, short, borrow, options and fund-flow data are missing.
Catalyst path 3/5 The first post-release session and next insurance filing are observable; only the first is near-dated.
Payoff architecture 2/5 The valuation sensitivity is reproducible, but P/B and subjective probabilities are weakly calibrated.
Invalidation discipline 4/5 Loss ratio, premiums, insurance underwriting earnings and consolidated operating earnings are monitorable.
Differentiated insight 4/5 Q3 weakness is isolated against 9M growth, while buybacks support the countercase without providing a floor.
Client value 4/5 The screen separates one-quarter operating weakness from GAAP investment marks and from executable short economics.
Total 27/40 Information screen only; the failed 10/5 gate controls the classification.

Sources

  1. Berkshire Hathaway Q3 2026 earnings release, Nov. 7
  2. Berkshire Hathaway Q3 2026 Form 10-Q
  3. BRK.B historical daily prices, ChartExchange
  4. BRK.B historical price data and source note, StockAnalysis
  5. BRK.B P/B history, methodology and estimated ranges, TGMCharts
  6. NRG Q3 2026 report schedule, issuer release
  7. NRG Q2 2026 results and guidance, issuer release
  8. NRG historical daily prices, ChartExchange
  9. OXY Q3 2026 report schedule, issuer release
  10. OXY Q2 2026 results, issuer release
  11. OXY historical daily prices, ChartExchange
  12. SPY historical daily prices, ChartExchange

Bottom Line

Berkshire’s Q3 insurance deterioration deserves attention; it does not make the stock a bounded short. The current 1.596x book multiple leaves room for compression, but the highest-probability base is flat and the adverse stress is more than twice the permitted loss bound. Keep the Reject classification, null entry and execution disabled.

AI Illustration Prompt

Create a restrained financial-editorial still life for The Mispricing Desk. On a deep graphite desk, place an open Berkshire quarterly filing with two legible lines: “Q3 insurance underwriting $1.352B vs $2.369B” and “9M operating earnings +8.0%.” Beside it, set a share-repurchase ledger stamped “Q3 reconstructed average ~$502.69,” next to a blank post-result quote panel labeled “first regular session pending.” Use paper ivory, slate, muted green and a small copper accent. Make the conflict between one weak quarter and durable capital explicit without stock arrows, rockets, cash piles or hero imagery. Add a subtle, readable “The Mispricing Desk” watermark along the lower edge of the ledger.